Cancer inhibitors trang 1 tải miễn phí từ TAILIEUCHUNG

"Cancer inhibitors" trang 1 - tải miễn phí từ Tailieuchung

Prediction of anticancer molecules using hybrid model developed on molecules screened against NCI-60 cancer cell lines

Prediction of anticancer molecules using hybrid model developed on molecules screened against NCI-60 cancer cell lines

10 66 1

Generation and characterization of MEK and ERK inhibitors- resistant non-smallcells-lung-cancer (NSCLC) cells

Generation and characterization of MEK and ERK inhibitors- resistant non-smallcells-lung-cancer (NSCLC) cells

7 44 1

Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer

Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer

9 36 1

Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells

Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells

17 40 1

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial

7 41 1

Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension - a real-world study

Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension - a real-world study

14 11 1

Comparison of the efficacies of firstgeneration epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced nonsmall-cell lung cancer harboring EGFR mutations

Comparison of the efficacies of firstgeneration epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced nonsmall-cell lung cancer harboring EGFR mutations

7 69 0

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: Causal modeling, timing, and classes of concomitant medications

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: Causal modeling, timing, and classes of concomitant medications

13 80 0

Diverse mechanisms activate the PI 3- kinase/mTOR pathway in melanomas: Implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Diverse mechanisms activate the PI 3- kinase/mTOR pathway in melanomas: Implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

12 41 1

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with antiprogrammed cell death-1/ligand 1 inhibitors

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with antiprogrammed cell death-1/ligand 1 inhibitors

8 79 0

STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers

STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers

14 73 0

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial

6 45 1

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: Therapeutic implications for immune checkpoint inhibitors

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: Therapeutic implications for immune checkpoint inhibitors

10 29 1

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: Realworld data in Korea

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: Realworld data in Korea

9 36 1

An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients

9 20 1

Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: Caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy

Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: Caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy

9 49 1

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma

13 63 1

Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer

Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer

9 40 1

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: Long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: Long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors

12 19 1

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial

10 36 1

Đầu
[ 1 ]
2
3
4
5
6
7
8
9
10
11
12
13
14
Cuối

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.